A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: Modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor

Clinical Cancer Research

Volumn 10, Issue 14, 2004, Pages 4680-4687

  Haddad, Robert I ^a,b   Weinstein, Lisa J ^b   Wieczorek, Tad J ^b   Bhattacharya, Nandita ^a   Raftopoulos, Harry ^c   Oster, Martin W ^c   Zhang, Xinxin ^a   Latham, Vaughan M ^a   Costello, Rosemary ^a   Faucher, Jarrod ^a   DeRosa, Carolyn ^c   Yule, Murray ^e   Miller, Linda P ^d   Loda, Massimo ^a,b   Posner, Marshall R ^a,b   Shapiro, Geoffrey I ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Howard Hughes Medical Institute   (United States)

^d EISAI INC   (United States)

^e Dana 810A ^*

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; CHLOROINDOLYLSULFONAMIDE; CYCLIN DEPENDENT KINASE; FLAVOPIRIDOL; INDISULAM; RETINOBLASTOMA PROTEIN; ROSCOVITINE; SULFONAMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; ASPIRATION BIOPSY; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE G1 PHASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; OROPHARYNX CANCER; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECURRENT CANCER; RESPIRATORY FAILURE; SQUAMOUS CELL CARCINOMA; SYNCOPE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 3242712108     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0229     Document Type: Article

References (45)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA - Cancer J Clin 2003;53:5-26.
2. Haddad RI, Wirth L, Posner MR. Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. Expert Rev. Anticancer Ther 2003;3:331-8.
3. Adelstein DJ. Systemic chemotherapy for squamous cell head and neck cancer. Expert Opin Pharmacother 2003;4:2151-63.
4. Kim ES, Glisson BS. Treatment of metastatic head and neck cancer: chemotherapy and novel agents. Cancer Treat Res 2003;114:295-314.
5. Shapiro GI, Harper JW. Anticancer drug targets: cell cycle and checkpoint control. J Clin Investig 1999;104:1645-53.
6. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst (Bethesda) 2000;92:376-87.
7. 1 cyclins. Cell 1993;73:1059-65.
8. 1-phase progression. Genes Dev 1999;13:1501-12.
9. Sherr CJ. Cancer cell cycles. Science (Wash. DC) 1996;274:1672-7.
10. 1-S cell cycle control in head and neck cancer: a review. Head Neck 2002;24:694-704.
11. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science (Wash. DC) 1993;262:2050-4.
12. Chen YNP, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999;96:4325-9.
13. van Kesteren C, Beijnen JH, Schellens JHM. E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. Anticancer Drugs 2002;13:989-97.
14. 1 phase. III. Studies of mechanism of action. Proc Am Assoc Cancer Res 1996;37:A2667.
15. Yokoi A, Kuromitsu J, Kawai T, et al. Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis. Mol Cancer Ther 2002;1:275-86.
16. Fukuoka K, Usuda J, Iwamoto Y, et al. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Investig New Drugs 2001;19:219-27.
17. Ozawa Y, Sugi NH, Nagasu T, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer 2001;37:2275-2282.
18. Raymond E, ten Bokkel Huinink WW, Taieb J, et al. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. J Clin Oncol 2002;16:3508-21.
19. van Kesteren C, Mathot RAA, Raymond E, et al. Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol 2002;20:4065-73.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst (Bethesda) 2000;92:205-16.
21. Talbot D, Norbury C, Slade M, et al. A Phase II and pharmacodynamic study of E7070 in patients with non-small cell lung cancer (NSCLC) who have failed platinum-based chemotherapy. Proc Am Soc Clin Oncol 2002;21:A1306.
22. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
23. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific cdk phosphorylation sites. J Biol Chem 1996;271:8313-20.
24. 1-S cyclin-dependent kinases. J Biol Chem 1997;272:12738-46.
25. Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 1997;8:287-301.
26. Magi-Galluzzi C, Mishra R, Fiorentino M, et al. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Investig 1997;76:37-51.
27. Jacobs C, Lyman G, Velez-Garcia E. A Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-63.
28. Kaplan E, Meier R. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
29. Shapiro GI. Small molecule inhibitors of cyclin-dependent kinases. In: Blagasklonny M, editor. Cell cycle checkpoints and cancer. Georgetown, TX: Landes Bioscience; 2001. p. 208-34.
30. Senderowicz AM. Small-molecule cyclin-dependent kinase inhibitors. Oncogene 2003;22:6609-20.
31. Bongard HJ, Pluim D, Waardenburg RC, Ravic M, Beijnen JH, Schellens JH. In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood. Anticancer Drugs 2003;14:405-10.
32. Yoo GH, Xu HJ, Breenan JA. Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Res 1994;54:4603-6.
33. Jung CP, Motwani MV, Schwartz GK. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of the ribonucleotide reductase M2 subunit. Clin Cancer Res 2001;7:2527-36.
34. Jiang J, Matranga CB, Cai D, et al. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Cancer Res 2003;63:7410-22.
35. Kip1. Genes Dev 1997;11:1464-78.
36. Kitagawa M, Higashi H, Suzuki-Takahashi I, et al. Phosphorylation of E2F-1 by cyclin A-cdk2. Oncogene 1995;10:229-36.
37. Ma T, Van Tine BA, Wei Y, et al. Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E-cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev 2000;14:2298-313.
38. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003;63:230-5.
39. van Oigen MGCT, Medema RH, Slootweg PJ, Rijksen G. Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol 1998;110:24-31.
40. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
41. Sasaki K, Murakami T, Kawasai M, Takahashi M. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol 1987;133:579-84.
42. Punt CJ, Fumoleau P, van de Walle B, Faber MN, Ravic M, Campone M. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors: a study by the EORTC-early clinical studies group (ECSG). Ann Oncol 2001;12:1289-93.
43. Terret C, Zanetta S, Roche H, et al. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours: a study by the EORTC Early Clinical Study Group (ECSG). Eur J Cancer 2003;39:1097-104.
44. Dittrich C, Dumez H, Calvert H, et al. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin Cancer Res 2003;9:5195-204.
45. Ozawa Y, Kai J, Kusano K, Makoto A, Yoshimatsu K. Synergistic effect of E7070 combined with CPT-11 in human tumor xenograft models. Clin Cancer Res 2000;6(Suppl):A502.